Trial Profile
A Randomized, Double-masked, Pilot Study of the Safety and Efficacy of 0.5 µg/Day and 0.2 µg/Day Iluvien (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg in Subjects With Macular Oedema Secondary to Retinal Vein Occlusion
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2015
Price :
$35
*
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Branch retinal vein occlusion; Central retinal vein occlusion; Retinal oedema
- Focus Therapeutic Use
- Acronyms FAVOR
- Sponsors Alimera Sciences
- 27 May 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov.
- 16 Sep 2014 New trial record